When was Lighthouse Pharma founded?

Lighthouse Pharma was founded in 2019 and raised its 1st funding round 6 years after it was founded.

Where is Lighthouse Pharma located?

Lighthouse Pharma is headquartered in San Francisco, United States.

How many employees does Lighthouse Pharma have?

As of Aug 31, 2026, the latest employee count at Lighthouse Pharma is 12.

Is Lighthouse Pharma a funded company?

Lighthouse Pharma is a funded company, having raised a total of $15.2M across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Dec 04, 2025.

When was the latest funding round of Lighthouse Pharma?

Lighthouse Pharma's latest funding was a $***** Series A round on Apr 22, 2026, with participation from 1 investor.

Where does Lighthouse Pharma rank among its competitors?

Lighthouse Pharma ranks 21st amongst 215 active competitors, of which 61 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Drug Farm, which secured $55M in Jul, 2026.

Who are the top competitors of Lighthouse Pharma?

Lighthouse Pharma's top competitors include Insightec, Drug Farm and LEXEO Therapeutics. Among them, Drug Farm secured the most recent funding round in July, 2026.

Lighthouse Pharma - 2026 Company Profile, Funding & Competitors

Lighthouse Pharma is a series A company based in San Francisco (United States), founded in 2019. It operates as a Developer of therapeutics for neurology and infectious diseases. Lighthouse Pharma has raised $15.2M in funding from Double Point Ventures. The company has 215 active competitors, including 61 funded and 24 that have exited. Its top competitors include companies like Insightec, Drug Farm and LEXEO Therapeutics.

Company Details

Developer of therapeutics for neurology and infectious diseases. It offers a pipeline of drug candidates which include LHP588, is a next-generation gingipain inhibitor for gingivalis infection which causes Alzheimer's disease, Parkinson's disease, and oral dyslapsia. It also offers LHP852 for gingivalis infection and LHP803 for coronavirus infection.

Website: www.lighthousepharma.com/
Email ID: *****@lighthousepharma.com

Key Metrics

Founded Year

2019

Location

San Francisco, United States

Stage

Series A

Total Funding

$15.2M in 2 rounds

Latest Funding Round

Series A, Apr 22, 2026, $*****

Investors

Double Point Ventures & 1 more

Ranked

21^st among 215 active competitors

Employee Count

12 as on Aug 31, 2026

Similar Companies

Drug Farm & 195 more

View Lighthouse Pharma's full profile

Lighthouse Pharma has raised a total funding of $15.2M over 2 rounds. Its first funding round was on Dec 04, 2025. Its latest funding round was a Series A round on Apr 22, 2026 for $*****. 1 investor participated in its latest round. Lighthouse Pharma has 2 institutional investors.

Here is the list of recent funding rounds of Lighthouse Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 22, 2026	2744454	Series A	3853264	5927432	4408930	4347223
Dec 04, 2025	7532684	Grant (prize money)	8420595	7756752	5108484	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Lighthouse Pharma's funding rounds and investors

Lighthouse Pharma's employee count trend

Lighthouse Pharma has 12 employees as of Aug 26. Here is Lighthouse Pharma's employee count trend over the years:

Employee count trend for Lighthouse Pharma

Uncover Lighthouse Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lighthouse Pharma include Insightec, Drug Farm and LEXEO Therapeutics. Here is the list of Top 10 competitors of Lighthouse Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Insightec 1999, Tirat Carmel (Israel), Series G	Manufacturer of focused ultrasound platforms for treating neurological movement disorders	$574M	GE HealthCare, Koch Disruptive Technologies ... & 27 others	67/100
2nd	Drug Farm 2015, Shanghai (China), Series D	Developer of a novel treatment for metabolic diseases	$138M	Shanghai Pudong Leading Area Investment Center, Zhejiang Private Enterprise United Investment ... & 13 others	65/100
3rd	LEXEO Therapeutics 2018, New York City (United States), Public	Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases	$185M	Eventide Funds, Frazier Life Sciences & 26 others	64/100
4th	Longeveron 2014, Miami (United States), Public	Developer of cellular therapies for aging-related and life-threatening conditions	$1.05M	Janus Henderson Investors, Logos & 6 others	62/100
5th	OncoC4 2020, Rockville (United States), Series B	Developer of immunotherapy for cancer patients	$50M	GBA Fund, 3E Bioventures Capital & 4 others	62/100
6th	RUBEDO LIFE SCIENCES 2018, Sunnyvale (United States), Series A	Developer of therapeutics for age-related diseases	$52M	Khosla Ventures, Ahren & 13 others	61/100
7th	Rejoni 2020, Bedford (United States), Series B	Developer of therapeutics to treat women health conditions	$66.3M	Ascension Ventures, CHV & 8 others	61/100
8th	Cassava Sciences 1998, Austin (United States), Public	Developer of small molecule-based therapeutic solutions for treating neurological diseases	-	Kosinski Ventures, NIH & 1 others	60/100
9th	Acumen Pharmaceuticals 1996, Livermore (United States), Public	Developer of monoclonal antibody therapeutics for Alzheimer's disease	$2.2M	ADAR1, Western Technology Investment & 6 others	59/100
10th	Gameto 2020, United States, Series C	Developer of therapeutics for the treatment of fertility and menopause	$127M	RA Capital Management, Two Sigma Ventures ... & 30 others	59/100
21st	Lighthouse Pharma 2019, San Francisco (United States), Series A	Developer of therapeutics for neurology and infectious diseases	$15.2M	Double Point Ventures, HHS	51/100